Immatics N.V.: An Intriguing Developmental Concern [Seeking Alpha]
Immatics N.V. - Ordinary Shares (IMTX)
Company Research
Source: Seeking Alpha
The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors. Immatics has collaborations with Bristol Myers Squibb totaling $4.2 billion in potential milestones. A full investment analysis around this intriguing developmental concern follows in the paragraphs below. Shares of European T-Cell receptor therapy concern Immatics N.V. ( NASDAQ: IMTX have traded predominantly below their initial trade on the NASDAQ in 2020 due to a dearth of clinical data. That drought will end in 2024 with readouts anticipated on Recommended For You Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
IMTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMTX alerts
High impacting Immatics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
IMTX
News
- Immatics (NASDAQ: IMTX) had its price target raised by analysts at Mizuho from $14.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Immatics Announces First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]Yahoo! Finance
- Immatics Announces First Quarter 2024 Financial Results and Business UpdateGlobeNewswire
- Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case [Seeking Alpha]Seeking Alpha
- Immatics Announces Full Year 2023 Financial Results and Corporate Update [Yahoo! Finance]Yahoo! Finance
IMTX
Earnings
- 11/14/23 - Beat
IMTX
Sec Filings
- 5/14/24 - Form 6-K
- 3/21/24 - Form 6-K
- 3/21/24 - Form 20-F
- IMTX's page on the SEC website